» Articles » PMID: 23606940

Diagnosis and Management of Congenital and Idiopathic Erythrocytosis

Overview
Specialty Hematology
Date 2013 Apr 23
PMID 23606940
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

An erythrocytosis occurs when there is an increased red-cell mass. The causes of erythrocytosis are divided into primary, when there is an intrinsic defect in the erythroid cell, and secondary, when the cause is extrinsic to the erythroid cell. An idiopathic erythrocytosis occurs when the increased red-cell mass has no identifiable cause. Primary and secondary defects can be further classified as either congenital or acquired causes. The diagnostic pathway starts with a careful history and examination followed by measurement of the erythropoietin (EPO) levels. This allows a division of those patients with a low EPO level, who can then be investigated for primary causes of erythrocytosis, and those with a normal or high EPO level, where the oxygen-sensing pathway needs to be explored further. Physiological studies in those with congenital defects in the oxygen-sensing pathway show many changes in the downstream metabolism adapting to the defect, which has a bearing on the management of the disorders. Low-dose aspirin and venesection to an achievable target are the main therapeutic options that can be considered in the management of erythrocytosis. Specific guidance on venesection options should be considered with certain causes such as high oxygen-affinity hemoglobins.

Citing Articles

Coexistence of Multiple Gene Variants in Some Patients with Erythrocytoses.

Benetti A, Bertozzi I, Ceolotto G, Cortella I, Regazzo D, Biagetti G Mediterr J Hematol Infect Dis. 2024; 16(1):e2024021.

PMID: 38468832 PMC: 10927185. DOI: 10.4084/MJHID.2024.021.


One gene, two opposite phenotypes: a case report of hereditary anemia due to a loss-of-function variant in the gene.

Rosato B, Marra R, Del Giudice F, Nostroso A, Gobbi S, Bruschi B Haematologica. 2023; 108(10):2872-2876.

PMID: 37102609 PMC: 10543174. DOI: 10.3324/haematol.2022.282457.


Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR-Reduced.

Ferreira J, Anker S, Butler J, Filippatos G, Iwata T, Salsali A Eur J Heart Fail. 2021; 24(4):708-715.

PMID: 34957660 PMC: 9303456. DOI: 10.1002/ejhf.2409.


Secondary erythrocytosis following drugs used in rifampicin/multidrug-resistant tuberculosis: a retrospective cohort study.

Tesfamariam S, Ghebrenegus A, Woldu H, Fisseha E, Belai G, Russom M BMJ Open Respir Res. 2021; 8(1).

PMID: 34815231 PMC: 8611426. DOI: 10.1136/bmjresp-2021-001064.


Diagnosis and management of non-clonal erythrocytosis remains challenging: a single centre clinical experience.

Anzej Doma S, Drnovsek E, Kristan A, Fink M, Sever M, Podgornik H Ann Hematol. 2021; 100(8):1965-1973.

PMID: 34013406 PMC: 8285333. DOI: 10.1007/s00277-021-04546-4.


References
1.
Jelkmann W, Lundby C . Blood doping and its detection. Blood. 2011; 118(9):2395-404. DOI: 10.1182/blood-2011-02-303271. View

2.
Percy M . Genetically heterogeneous origins of idiopathic erythrocytosis. Hematology. 2007; 12(2):131-9. DOI: 10.1080/10245330601111979. View

3.
McMullin M, Bareford D, Campbell P, Green A, Harrison C, Hunt B . Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol. 2005; 130(2):174-95. DOI: 10.1111/j.1365-2141.2005.05535.x. View

4.
Smith T, Brooks J, Balanos G, Lappin T, Layton D, Leedham D . Mutation of the von Hippel-Lindau gene alters human cardiopulmonary physiology. Adv Exp Med Biol. 2007; 605:51-6. DOI: 10.1007/978-0-387-73693-8_9. View

5.
Johansson P, Safai-Kutti S, Kutti J . An elevated venous haemoglobin concentration cannot be used as a surrogate marker for absolute erythrocytosis: a study of patients with polycythaemia vera and apparent polycythaemia. Br J Haematol. 2005; 129(5):701-5. DOI: 10.1111/j.1365-2141.2005.05517.x. View